NCT04761653

Brief Summary

Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence, and therapeutic strategies are limited. There is a need for novel treatment strategies, such as immuotherapy. This is a retrospective study including 84 patients with primary diagnosis of atypical meningiomas. The presence of T cells (CD4, CD8, Treg and memory T cells) and mature dendritic cells will be quantified on whole tissue sections stained by immunohistochemistry (CD4, CD8, FOXP3, CD45RO and CD208). This could allow us to identify novel biomarkers for survival, and facilitate the selection of patients who may benefit from immunotherapeutic modalities.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
84

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 16, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 21, 2021

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2021

Completed
Last Updated

February 21, 2021

Status Verified

February 1, 2021

Enrollment Period

6 months

First QC Date

February 16, 2021

Last Update Submit

February 16, 2021

Conditions

Atypical Meningioma

Outcome Measures

Primary Outcomes (1)

  • Progression free survival

    2-21 years

Secondary Outcomes (1)

  • Overall survival

    2-21 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients operated for a cerebral tumor, with primary diagnosis of atypical meningioma

You may qualify if:

  • primary diagnosis of atypical meningioma
  • surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guillaume GAUCHOTTE

Vandœuvre-lès-Nancy, 54511, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

FFPE tissue block

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PU PH

Study Record Dates

First Submitted

February 16, 2021

First Posted

February 21, 2021

Study Start

January 1, 2021

Primary Completion

June 30, 2021

Study Completion

June 30, 2021

Last Updated

February 21, 2021

Record last verified: 2021-02

Locations

FR(1)